Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CST-3056 in Neurogenic Orthostatic Hypotension
NCT07089043Phase 2Active, not recruiting
- Sponsor
- CuraSen Therapeutics
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of CST-3056 in Neurogenic Orthostatic Hypotension (nOH) (2 arms), sponsored by CuraSen Therapeutics. Primary endpoint: Change from Baseline in Standing Systolic Blood Pressure. Started Sep 2025; status: active, not recruiting.
02
Drugs
CST-3056
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on NCT07089043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07089043.